A citation-based method for searching scientific literature

Bruce Neal, Vlado Perkovic, Dick de Zeeuw, Kenneth W Mahaffey, Greg Fulcher, Kirk Ways, Mehul Desai, Wayne Shaw, George Capuano, Maria Alba, Joel Jiang, Frank Vercruysse, Gary Meininger, David Matthews. Diabetes Care 2015
Times Cited: 156



D Devineni, L Morrow, M Hompesch, D Skee, A Vandebosch, J Murphy, K Ways, S Schwartz. Diabetes Obes Metab 2012
Times Cited: 179




List of shared articles



Times cited

SGLT1 inhibition boon or bane for diabetes-associated cardiomyopathy.
Jaspreet Kalra, Suresh Babu Mangali, Deepika Dasari, Audesh Bhat, Srashti Goyal, Indu Dhar, Dharamrajan Sriram, Arti Dhar. Fundam Clin Pharmacol 2020
3

Improving postprandial hyperglycemia in patients with type 2 diabetes already on basal insulin therapy: Review of current strategies.
Guillermo E Umpierrez, Timothy S Bailey, Danielle Carcia, Charles Shaefer, Jay H Shubrook, Neil Skolnik. J Diabetes 2018
8

The Association Between the Dosage of SGLT2 Inhibitor and Weight Reduction in Type 2 Diabetes Patients: A Meta-Analysis.
Xiaoling Cai, Wenjia Yang, Xueying Gao, Yifei Chen, Lingli Zhou, Simin Zhang, Xueyao Han, Linong Ji. Obesity (Silver Spring) 2018
46

Pharmacokinetics and pharmacodynamics of canagliflozin in pediatric patients with type 2 diabetes.
William V Tamborlane, David Polidori, Domenick Argenti, Nicholas A Di Prospero. Pediatr Diabetes 2018
1

A practical approach and algorithm for intensifying beyond basal insulin in type 2 diabetes.
Ronald M Goldenberg, Peter Assimakopoulos, Jeremy D Gilbert, Irving S Gottesman, Jean-Fran├žois Yale. Diabetes Obes Metab 2018
0

SGLT2 Inhibition for the Prevention and Treatment of Diabetic Kidney Disease: A Review.
Radica Z Alicic, Emily J Johnson, Katherine R Tuttle. Am J Kidney Dis 2018
46


Longer-term safety and tolerability of canagliflozin in patients with type 2 diabetes: a pooled analysis.
Rong Qiu, Dainius Balis, John Xie, Michael J Davies, Mehul Desai, Gary Meininger. Curr Med Res Opin 2017
20

A review of clinical efficacy and safety of canagliflozin 300 mg in the management of patients with type 2 diabetes mellitus.
K M Prasanna Kumar, Sujoy Ghosh, William Canovatchel, Nishant Garodia, Sujith Rajashekar. Indian J Endocrinol Metab 2017
7



Tolerability of canagliflozin in patients with type 2 diabetes mellitus fasting during Ramadan: Results of the Canagliflozin in Ramadan Tolerance Observational Study (CRATOS).
Mohamed Hassanein, Akram Echtay, Ahmed Hassoun, Monira Alarouj, Bachar Afandi, Raffi Poladian, Abdullah Bennakhi, Maciej Nazar, Paul Bergmans, Sofia Keim,[...]. Int J Clin Pract 2017
22

Sodium-glucose Cotransporter-2 Inhibitors: Moving Beyond the Glycemic Treatment Goal.
Vishal Gupta, William Canovatchel, B N Lokesh, Ravi Santani, Nishant Garodia. Indian J Endocrinol Metab 2017
0